HK Innoen announced its plans to operate the cytogene therapy business as an innovation platform through the 39th’JP Morgan Healthcare Conference’ emerging market track at 10:05 pm on the 13th. The presentation will be presented by Song Geun-suk (CTO), head of the R&D division.
|
The JPMorgan Healthcare Conference is the world’s largest bio-investment event held in January every year, and this year, it is being held online from 11-14 (local time) considering the situation of the Corona 19 pandemic. HK Innoen participated in the conference for the first time.
HK Inoen is focusing on the development of immune cytogenetic therapy products with high market access among cytogene therapy products. A typical example is CAR-T treatment, which kills cancer cells by genetically engineering the patient’s immune T cells in vitro and then injecting them back into the patient. According to The Business Research Company, the CAR-T treatment market among immune cytogenetic drugs is expected to grow to 11 trillion won in 2025.
Because of its high growth potential, global bio companies are jumping into related R&D. Last year, Bayer, Germany, acquired Ascrepios Pio Pharmaceuticals (Askbio) for about $4 billion (4.5 trillion won) to strengthen its cytogene therapy pipeline.
HK Innoen has already built a related production facility in Gyeonggi-do and has been operating since last year. It also secured a manpower specialized in cytogenetic therapy products centering on hematological and solid cancers. Through global partnerships, the latest technologies and challenges are jointly or self-developed and the pipeline is reinforced. It is pursuing the introduction of technology from overseas partners, and plans to announce targets for developing candidate substances and drugs soon. An official from HK Innoen said, “Since there are only a few new drugs released and they have advanced into multinational pharmaceutical companies, we expect this market to have a high growth potential,” he said. “We will disclose details of the business plan as soon as the technology introduction contract is reached.”
|
HK Innoen plans to announce its growth potential by introducing domestic and overseas achievements and features of’K-Cap Tablet (ingredient name Tegoprazan)’, a gastroesophageal reflux disease drug, the 30th domestic drug through an announcement on this day. K-cap tablet was released in 2019 after receiving domestic approval in 2018. It has been exported to 25 overseas countries such as China, Vietnam, and Singapore, and is undergoing new drug approval procedures in each country. According to Chinese partner Luo Shinsa, it is expected to be released in China around 2022. In the US, it was approved for phase 1 clinical trials in May last year.
In addition, a new drug for autoimmune disease (IN-A002) and a new drug for nonalcoholic steatohepatitis (IN-A010) in phase 1 clinical trials in Korea, new anticancer drugs (IN-A008, IN-A013) scheduled for phase 2 clinical trials in Europe and 2 The family plans to announce the research results and future plans of major new drugs and bio pipelines such as hand, foot and mouth vaccine (IN-B001).
It is interpreted that HK Innoen’s entry into new business and the announcement of a new drug pipeline is in line with the strengthening of the pharmaceutical and bio business within Kolmar Korea. Kolmar Korea acquired CJ Healthcare in 2018 and changed its name to HK Innoen. Afterwards, it concluded the sale of Kolmar Korea and Kolma Pharma, placing HK Innoen at the center of the pharmaceutical business. It is a policy to accelerate listing in the business area by promoting listing within this year.
Kang Seok-hee, CEO of HK Innoen, said, “At the JP Morgan Healthcare Conference, we plan to spread the company’s performance and future growth engines to the domestic and international markets.” “The business capability and R&D capability between the company and partners meet to create the best synergy. We will also consider various forms of collaboration, such as strategic investment, export of core technologies and products, and joint research.”